Perret et al. demonstrated adding the adjuvant Poly(I:C) to the vaccine increased ratios of tumor antigen-specific effector T cells: regulatory T cells that enhanced the infiltration of CD8+ T-cell, thus promoting anti-tumor immunity. Here, CD8A is linked to neoplasm.